Clinical Trial Update: Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety and efficacy of AFQ056 in adults with Fragile X Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Fragile X Syndrome | Phase 2 | Status: COMPLETED